Back to top
more

Merit Medical Systems (MMSI)

(Real Time Quote from BATS)

$73.92 USD

73.92
2,100

+0.14 (0.19%)

Updated Apr 29, 2024 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View

by Zacks Equity Research

Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

by Zacks Equity Research

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.

Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

by Zacks Equity Research

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

by Zacks Equity Research

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

by Zacks Equity Research

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Microbot Medical (MBOT) Announces Positive GLP Study Results

by Zacks Equity Research

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.

MMSI or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MMSI vs. WST: Which Stock Is the Better Value Option?

Why Merit Medical (MMSI) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

PDCO or MMSI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery

by Zacks Equity Research

Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.

Reasons to Add Patterson Companies (PDCO) in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes

by Zacks Equity Research

Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.